Punit Dhillon

Executive

Chairman & CEO

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 1 saleDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€1,919

Latest filing published 07 Aug 2026 for Skye Bioscience, Inc.. Read the official filing

Filing timeline

BuySale

Punit Dhillon

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

No signal scores available.

Punit Dhillon: trading record in brief

Punit Dhillon, listed as chief executive, appears in our data through filings on Skye Bioscience, Inc. shares, published by SEC (Form 4). We count 10 filings; the first trade dates from 14 December 2021 and the latest from 7 August 2026.

Sales make up the whole of the open-market record (1 sale, €1,919). Besides market trades, the filings include 8 share grants.

Most recently, on 7 August 2026, the filings show a share grant in Skye Bioscience, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.